<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Current Issue</title>
    <link>https://jamanetwork.com/journals/jama</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 20 Feb 2018 11:43:23 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>jamams@jamanetwork.org</managingEditor>
    <webMaster>support@jamanetwork.com</webMaster>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673135">
      <title>Highlights for February 20, 2018</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673135</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author />
      <description />
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">633</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">635</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.12240</prism:doi>
      <guid>2673135</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2671354">
      <title>Does Medicine Overemphasize IQ?</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2671354</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Emanuel EJ, Gudbranson E. </author>
      <description>&lt;span class="paragraphSection"&gt;In this Viewpoint, Ezekiel Emanuel argues that emotional intelligence (EQ) is as important as IQ for the effective practice of medicine and calls for medical schools to evaluate the EQ of applicants and provide opportunities to enhance EQ among medical students.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">651</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">652</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.20141</prism:doi>
      <guid>2671354</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2671355">
      <title>Principles for a Framework for Alternative Payment Models</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2671355</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Nussbaum S, McClellan M, Metlay G. </author>
      <description>&lt;span class="paragraphSection"&gt;This Viewpoint describes the Health Care Payment Learning and Action Network’s alternative payment model classification system and its framework principles.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">653</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">654</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.20226</prism:doi>
      <guid>2671355</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2666233">
      <title>Accountable Care at the Frontlines of a Health System</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2666233</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Ganguli I, Ferris TG. </author>
      <description>&lt;span class="paragraphSection"&gt;This Viewpoint discusses tensions between the goals and realities of accountable care organizations and suggests ways for health system leaders to address these issues and improve health care quality and reduce costs.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">655</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">656</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.18995</prism:doi>
      <guid>2666233</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673153">
      <title>Teaching Internal Medicine Residents About Palliative Care</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673153</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Rosenberg LB. </author>
      <description>&lt;span class="paragraphSection"&gt;In this essay, a palliative care physician reviews the case of a dying man who was admitted during her two-week tour as an attending physician for internal medicine as a good teaching case for residents to learn how to treat patients in the last moments of their lives.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">657</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">658</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0071</prism:doi>
      <guid>2673153</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673130">
      <title>Preventing Delirium in the ICU</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673130</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Delaney A, Hammond N, Litton E. </author>
      <description>&lt;span class="paragraphSection"&gt;Delirium is a complex problem, has a poorly understood pathophysiology, and usually manifests as a fluctuating disturbance of consciousness and cognition that develops over a short period and is associated with physical or mental illness. Delirium is not exclusively a complication of critical illness but develops in approximately one-third of patients treated in intensive care units (ICUs). The majority of these patients experience hypoactive delirium, a quietly confused state, rather than the more notable cases of agitated delirium, which present as overt hallucinations and hyperactivity.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">659</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">660</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0159</prism:doi>
      <guid>2673130</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673128">
      <title>Disentangling Health Care Billing</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673128</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Lee VS, Blanchfield BB. </author>
      <description>&lt;span class="paragraphSection"&gt;For many physicians, the term &lt;span style="font-style:italic;"&gt;administration&lt;/span&gt; elicits a negative response. In fact, some administrative tasks and expenses, such as quality improvement personnel, cybersecurity, backup generators, and even parking, are necessary to enhance patient experience and care. Other expenses, most notably related to billing and insurance-related activities, seem less justifiable.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">661</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">663</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.19966</prism:doi>
      <guid>2673128</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673129">
      <title>Time to Rethink the Approach to Treating Acute Respiratory Distress Syndrome</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673129</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Gattinoni L, Marini JJ, Quintel M. </author>
      <description>&lt;span class="paragraphSection"&gt;In this issue of &lt;span style="font-style:italic;"&gt;JAMA&lt;/span&gt;, Fan et al review the treatment of acute respiratory distress syndrome (ARDS), focusing on recent randomized clinical trials (RCTs). Most of these RCTs failed to show that the interventions that were tested offered significant benefit. These predominantly negative results may prompt the question of whether other rational and more-effective ways are available to increase knowledge and improve treatment of a syndrome that is common, deadly, and arguably emblematic of modern intensive care. Although many of these trials were admirably executed, their failure to demonstrate benefit may often have been due to uncertainties regarding enrollment criteria and imprecise deployment of the interventions that were being tested. &lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">664</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">666</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.21900</prism:doi>
      <guid>2673129</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673150">
      <title>Low-Fat vs Low-Carbohydrate Diet on Weight Loss in Overweight Adults</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673150</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Gardner CD, Trepanowski JF, Del Gobbo LC, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;This randomized clinical trial compares the effects of a healthy low-fat vs a healthy low-carbohydrate diet on 12-month weight change among adults aged 18 to 50 years with a body mass index of 28 to 40 without diabetes, and investigates modification of the diet effect by genotype pattern or insulin secretion.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">667</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">679</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0245</prism:doi>
      <guid>2673150</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673149">
      <title>Effect of Haloperidol on Survival Among Critically Ill Adults at High Risk of Delirium</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673149</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>van den Boogaard M, Slooter AC, Brüggemann RM, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;This randomized clinical trial compares the effects of prophylactic haloperidol on 28-day survival in patients in the intensive care unit at high risk of developing delirium.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">680</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">690</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0160</prism:doi>
      <guid>2673149</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673148">
      <title>Costs Associated With Physician Billing and Insurance-Related Activities</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673148</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Tseng P, Kaplan RS, Richman BD, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;This study estimates the administrative costs associated with physician billing activities in a large academic health care system with a certified electronic health record system.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">691</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">697</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.19148</prism:doi>
      <guid>2673148</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673154">
      <title>Acute Respiratory Distress Syndrome</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673154</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Fan E, Brodie D, Slutsky AS. </author>
      <description>&lt;span class="paragraphSection"&gt;This review summarizes advances in the diagnosis and treatment of acute respiratory distress syndrome between 2012 and 2017.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">698</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">710</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.21907</prism:doi>
      <guid>2673154</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673134">
      <title>Management of Acute Respiratory Distress Syndrome (ARDS) in Adults</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673134</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Howell MD, Davis AM. </author>
      <description>&lt;span class="paragraphSection"&gt;This JAMA Clinical Guidelines Synopsis summarizes the 2017 American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine guideline on management of acute respiratory distress syndrome (ARDS) in adults.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">711</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">712</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0307</prism:doi>
      <guid>2673134</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2672333">
      <title>Ulcerated Nodule of the Fingernail</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2672333</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Lipner SR. </author>
      <description>&lt;span class="paragraphSection"&gt;A woman receiving immunosuppressant therapy after a prior kidney transplant presented with a tender ulcerated nodule on her fingernail with nail loss, purulent drainage, and histopathology showing a pyogenic granuloma–like response with atypical epithelioid and spindled cells adjacent to blood vessels. What would you do next?&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">713</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">714</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0179</prism:doi>
      <guid>2672333</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673138">
      <title>Prevalence of Housing Problems Among Community Health Center Patients</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673138</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Baggett TP, Berkowitz SA, Fung V, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;This study uses national survey data to assess the prevalence and health-related correlates of housing problems among community health center patients.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">717</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">719</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.19869</prism:doi>
      <guid>2673138</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673142">
      <title>Organ Dysfunction After Individualized or Standard Blood Pressure Management</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673142</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Karamchandani K, Carr ZJ, Bonavia A. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;strong&gt;To the Editor&lt;/strong&gt; In a randomized clinical trial, Dr Futier and colleagues assessed the effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction. We had concerns regarding the blood pressure goals that were established for the subgroup of patients that was assigned to the standard blood pressure group.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">719</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">719</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.20935</prism:doi>
      <guid>2673142</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673144">
      <title>Organ Dysfunction After Individualized or Standard Blood Pressure Management</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673144</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Mitchell K, Adams D, McHugh SM. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;strong&gt;To the Editor&lt;/strong&gt; Dr Futier and colleagues performed a study to evaluate the effects of targeting perioperative blood pressure based on patients’ individual preoperative blood pressures compared with standard practice. However, methodological issues raise questions about the results. The authors did not simply compare 2 groups with different perioperative blood pressure goals. Rather, they compared the outcomes of 2 completely different blood pressure management strategies.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">719</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">720</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.20948</prism:doi>
      <guid>2673144</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673139">
      <title>Organ Dysfunction After Individualized or Standard Blood Pressure Management</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673139</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Thiele RH. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;strong&gt;To the Editor&lt;/strong&gt; A randomized clinical trial comparing a standard blood pressure management regimen vs individualized therapy in patients undergoing major surgery suggested that individualized goals could reduce postoperative organ dysfunction. Unfortunately, the conclusions of the Intraoperative Norepinephrine to Control Arterial Pressure (INPRESS) study are not fully supported by the data.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">720</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">720</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.20923</prism:doi>
      <guid>2673139</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673141">
      <title>Organ Dysfunction After Individualized or Standard Blood Pressure Management</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673141</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Daoud M. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;strong&gt;To the Editor&lt;/strong&gt; Dr Futier and colleagues concluded that management targeting an individualized SBP minimized the risk of postoperative organ dysfunction compared with standard management. The authors used a composite primary outcome. Composite outcomes should include components that are of comparable severity and occur with similar frequency. It was not appropriate to combine the less severe and more common RIFLE (risk, injury, failure, loss of kidney function, and end-stage kidney disease) stage risk with the more severe and less common myocardial infarction, nor a Glasgow Coma Scale score of 14 or less with stroke. The incidence of acute kidney dysfunction was relatively large, so that it overwhelmed the other components of the composite primary outcome and effectively became the primary outcome.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">720</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">721</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.20931</prism:doi>
      <guid>2673141</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673140">
      <title>Organ Dysfunction After Individualized or Standard Blood Pressure Management</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673140</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Laffin LJ, Laffin MR. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;strong&gt;To the Editor&lt;/strong&gt; In a recent study, individualized perioperative blood pressure management compared with standard care in the setting of major surgery was found to reduce the risk of postoperative organ dysfunction. Although the study was hypothesis generating, the manner and rigor with which reference or normal resting blood pressure was obtained warrants further explanation.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">721</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">721</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.20927</prism:doi>
      <guid>2673140</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673146">
      <title>Organ Dysfunction After Individualized or Standard Blood Pressure Management—Reply</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673146</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Futier E, Pereira B, Jaber S. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;strong&gt;In Reply&lt;/strong&gt; Dr Karamchandani and colleagues suggest that exposing patients in the standard treatment group to a blood pressure threshold level lower than what is generally accepted may have predisposed patients to organ dysfunction. However, although there is accumulating evidence that intraoperative blood pressure is associated with outcomes, the goals for blood pressure are not well supported by robust evidence and there are few data to support any specific threshold.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">721</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">722</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.20956</prism:doi>
      <guid>2673146</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673143">
      <title>Authorship Credit for Large Clinical Trials</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673143</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Wilkinson ST, Sanacora G. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;strong&gt;To the Editor&lt;/strong&gt; Drs Mentzelopoulos and Zakynthinos outlined the goals for maintaining the academic integrity of research in a Viewpoint. However, the current structure of promotions in most academic settings discourages rather than promotes collaboration. This current structure is not good for clinical research, as it perpetuates, rather than helps to resolve, the continuing problem that the majority of clinical trials are relatively small, single-site studies that may be underpowered and of questionable significance and potential to advance medicine. In clinical research involving human participants, high statistical variability is frequently seen. Thus, high-quality, meaningful research usually means large sample sizes. Except in rare cases, this requires collaboration among large groups of researchers. Under the present criteria for academic promotion at many universities, whereby investigators are heavily rewarded for either first or last authorship and promoted based largely on individual rather than collaborative efforts, the motivation to participate in large collaborative efforts is markedly diminished.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">722</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">723</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.20939</prism:doi>
      <guid>2673143</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673145">
      <title>Authorship Credit for Large Clinical Trials—Reply</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673145</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Mentzelopoulos SD, Zakynthinos SG. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;strong&gt;In Reply&lt;/strong&gt; Drs Wilkinson and Sanacora propose broader distribution of authorship credit to augment involvement of academic researchers in randomized clinical trials (RCTs) and boost the multicenter evaluation of “preventive, diagnostic, and therapeutic interventions.” Despite current stringent authorship guidelines, data suggest that the number of mainly industry-sponsored, multinational RCTs is increasing, as are the proportions of large RCTs recruiting patients in 3 or more to more than 10 nations and more than 1 continent. These data suggest expansion of international collaborative networks associated with well-designed research projects to provide high-quality published evidence on potentially beneficial interventions.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">723</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">724</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.20943</prism:doi>
      <guid>2673145</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673127">
      <title>Error in Figure</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673127</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author />
      <description>&lt;span class="paragraphSection"&gt;In the Original Investigation entitled “Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012” published in the January 9, 2018, issue of &lt;span style="font-style:italic;"&gt;JAMA&lt;/span&gt;, an incorrect label was used in Figure 2A. In the key of Figure 2A, "SEER" should be "Observed US mortality." This article was corrected online.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">724</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">724</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0632</prism:doi>
      <guid>2673127</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673125">
      <title>Incorrect Data in Tables</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673125</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author />
      <description>&lt;span class="paragraphSection"&gt;In the Original Investigation entitled “Association of Blood Transfusion From Female Donors With and Without a History of Pregnancy With Mortality Among Male and Female Transfusion Recipients” published in the October 17, 2017, issue of &lt;span style="font-style:italic;"&gt;JAMA&lt;/span&gt;, incorrect data were reported in tables. In Tables 2 and 3, the values reported in the “No. of Deaths Among Recipients/No. of Recipients” columns in the “Male Recipients” and “Female Recipients” sections should have been the numbers of ever-pregnant or never-pregnant female donors minus the numbers of male donors (reference category), rather than the total numbers of deaths and recipients. This article was corrected online.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">724</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">724</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0314</prism:doi>
      <guid>2673125</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673126">
      <title>Omitted Conflict of Interest Disclosures</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673126</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author />
      <description>&lt;span class="paragraphSection"&gt;In the Original Investigation entitled “Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet,” published in the November 28, 2017, issue of &lt;span style="font-style:italic;"&gt;JAMA&lt;/span&gt;, there were omissions in the Conflict of Interest Disclosures section. The following disclosures should have been included: “Dr Bhasin reported receiving research grants from the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Child Health and Human Development, the National Institute on Aging, the National Institute of Nursing Research, Abbott, Ligand, Transition Therapeutics, Regeneron, Novartis, Althea, Biosensics, and Merck; receiving consulting fees from Sanofi and Regeneron; serving as the chair of the Endocrine Society’s expert panel that developed guideline for testosterone therapy of androgen deficiency in men; and serving on the American Board of Internal Medicine Endocrinology Board’s examination writing committee from 2006 to 2015 and as this committee’s chair from 2011 to 2015.” This article was corrected online.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">724</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">724</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0613</prism:doi>
      <guid>2673126</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2671710">
      <title>ASO Therapy: Hope for Genetic Neurological Diseases</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2671710</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Muth CC. </author>
      <description>&lt;span class="paragraphSection"&gt;This medical news interview discusses recent advances in antisense oligonucleotide therapies.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">644</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">646</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.18665</prism:doi>
      <guid>2671710</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673136">
      <title>The Problem With Work Requirements for Medicaid</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673136</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Carroll AE. </author>
      <description>&lt;span class="paragraphSection"&gt;In November, the Trump administration announced that it would be &lt;a href="https://www.nytimes.com/2017/11/07/us/politics/trump-work-requirements-medicaid.html"&gt;more open to proposals&lt;/a&gt; from states that impose work requirements for Medicaid. In other words, it would allow states to apply restrictions on “able-bodied” adults who might apply for the program. This is an abrupt change from the Obama administration, which supported Medicaid eligibility by income levels, regardless of whether people had jobs or not.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">646</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">647</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0420</prism:doi>
      <guid>2673136</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673161">
      <title>Air Pollutants Undermine Infant Brain Development</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673161</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Friedrich MJ. </author>
      <description>&lt;span class="paragraphSection"&gt;Toxic air poses a threat to brain development in 17 million infants younger than 1 year who live in areas around the world where outdoor air pollution is at least 6 times higher than international limits, according to a &lt;a href="https://www.unicef.org/media/media_101774.html"&gt;report&lt;/a&gt; from the United Nations Children’s Fund (UNICEF). More than 12 million infants live in South Asia, and 4.3 million live in the East Asia and Pacific region. Many of these infants live in impoverished areas where they are subject to numerous environmental threats.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">648</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">648</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0966</prism:doi>
      <guid>2673161</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673160">
      <title>High Rates of Violent Death Among Rohingya</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673160</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Friedrich MJ. </author>
      <description>&lt;span class="paragraphSection"&gt;Violence was the direct cause of death for at least 6700 Rohingya civilians, including 730 children, living in the state of Rakhine, Myanmar, in the initial 31 days following the latest upsurge of unrest that began on August 25, 2017, according to &lt;a href="http://www.msf.org/en/article/myanmarbangladesh-msf-surveys-estimate-least-6700-rohingya-were-killed-during-attacks"&gt;surveys&lt;/a&gt; conducted by Médecins Sans Frontières (MSF).&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">648</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">648</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0964</prism:doi>
      <guid>2673160</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673159">
      <title>Inflammatory Bowel Disease Goes Global</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673159</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Friedrich MJ. </author>
      <description>&lt;span class="paragraphSection"&gt;Since 1990, the rates of inflammatory bowel diseases (IBD) have been increasing in newly industrialized countries in Asia, Africa, South America, and the Middle East, according to a &lt;a href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32448-0/abstract"&gt;report&lt;/a&gt; from an international group of researchers.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">648</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">648</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0365</prism:doi>
      <guid>2673159</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673133">
      <title>Crackdown on Stem Cell Product</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673133</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Voelker R. </author>
      <description>&lt;span class="paragraphSection"&gt;A New Jersey–based company that processes and stores stem cell products derived from human adipose tissue has run aground of FDA regulations.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">649</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">649</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0486</prism:doi>
      <guid>2673133</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673132">
      <title>Shock Waves for Diabetic Foot Ulcers</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673132</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Voelker R. </author>
      <description>&lt;span class="paragraphSection"&gt;The FDA has &lt;a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm590784.htm"&gt;approved&lt;/a&gt; the first shock wave device indicated for patients with diabetic foot ulcers.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">649</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">649</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0480</prism:doi>
      <guid>2673132</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673131">
      <title>Notable Year for Novel Drugs</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673131</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Voelker R. </author>
      <description>&lt;span class="paragraphSection"&gt;During 2017, the FDA’s Center for Drug Evaluation and Research (CDER) ushered 46 &lt;a href="https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ReportsBudgets/UCM591976.pdf?utm_campaign=Subscribe&amp;amp;utm_source=hs_email&amp;amp;utm_medium=email&amp;amp;utm_content=59975857&amp;amp;_hsenc=p2ANqtz-_FA_-ZoYrD6zGMvCgMIRfonSYNvo9nZum3csOddGgpuuadPjiwz_eCEmKsnGyAUKA3fcx1CRn-j5oZ69umtLrny9jS6a6blNOGyFZaJeqQIkd9Hj0&amp;amp;_hsmi=59975857"&gt;novel drugs&lt;/a&gt; through the approval process, the highest number per year over the last 10 years.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">649</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">649</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0477</prism:doi>
      <guid>2673131</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2670101">
      <title>A Facial Plastic Surgeon’s Review of  Wonder </title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2670101</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Tollefson TT. </author>
      <description>&lt;span class="paragraphSection"&gt;In this Arts and Medicine essay, a facial plastic and reconstructive surgeon who works with children with craniofacial differences reality checks R. J. Palacio’s story &lt;span style="font-style:italic;"&gt;Wonder&lt;/span&gt; about a boy with Treacher Collins syndrome starting his first year of school among peers.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">640</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">642</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.22109</prism:doi>
      <guid>2670101</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673152">
      <title>Not Wanting</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673152</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Pucciani D. </author>
      <description>&lt;span class="paragraphSection"&gt;No desire left. It has been buriedin the house on the hillamong the mounded cypresses shouldering the horizon. It wants to not want any more.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">725</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">725</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.13827</prism:doi>
      <guid>2673152</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673137">
      <title>Medical Research and the Golden Rule</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673137</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author />
      <description>&lt;span class="paragraphSection"&gt;Recent phenomenal innovations and discoveries in medical science have prompted reexamination of ethical standards in experimentation. In the ensuing discussions and controversies, medical ethics has been defined in moral, legal, sociologic, theologic, and many other terms, and its limitations, flexibility, and function have been widely articulated and debated. But the essence of medical ethics, the golden rule, has been largely overlooked or undervalued: “Whatsoever ye would that men should do to you, do ye even so to them” (Matthew 7:12).&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">726</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">726</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.12248</prism:doi>
      <guid>2673137</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673151">
      <title>Acute Respiratory Distress Syndrome</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673151</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author>Stevens JP, Law A, Giannakoulis J. </author>
      <description>&lt;span class="paragraphSection"&gt;This JAMA Patient Page describes acute respiratory distress syndrome (ARDS) and its risk factors, treatment, and long-term effects.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">732</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">732</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2018.0483</prism:doi>
      <guid>2673151</guid>
    </item>
    <item rdf="https://jamanetwork.com/journals/jama/fullarticle/2673155">
      <title>JAMA</title>
      <link>https://jamanetwork.com/journals/jama/fullarticle/2673155</link>
      <pubDate>Tue, 20 Feb 2018 00:00:00 GMT</pubDate>
      <author />
      <description />
      <prism:volume xmlns:prism="prism">319</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">637</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">638</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jama.2017.12241</prism:doi>
      <guid>2673155</guid>
    </item>
  </channel>
</rss>